Public Offerings, Clinical Tests, and Financial Results- Research Report on InterMune, Emergent BioSolutions, ImmunoGen, Sequenom, and Intrexon PR Newswire NEW YORK, November 13, 2013 NEW YORK, November 13, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting InterMune Inc. (NASDAQ: ITMN), Emergent BioSolutions, Inc. (NYSE: EBS), ImmunoGen Inc. (NASDAQ: IMGN), Sequenom Inc. (NASDAQ: SQNM), and Intrexon Corporation (NYSE: XON). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. InterMune Inc. Research Report On November 5, 2013, InterMune Inc. (InterMune) announced that it has agreed to sell 6.5 million shares of its common stock in an underwritten public offering at a price of $13.00 per share to the public. InterMune informed that it has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock regarding the offering. The Company stated that it estimates net proceeds from the offering to be approximately $79.6 million (assuming no exercise of the underwriters' option to purchase additional shares of common stock), excluding underwriting discounts and commissions and estimated offering expenses. InterMune added that it plans to use the net proceeds from the offering to fund the commercialization of Esbriet and its ASCEND clinical trial for U.S. registration of Esbriet, to advance the company's strategic initiatives, clinical trials supporting the use of Esbriet in idiopathic pulmonary fibrosis (IPF), expanding anti-fibrotic research program, and for general corporate purposes. Lastly, the Company stated that it expects to close this transaction around November 12, 2013. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/dd8c_ITMN] -- Emergent BioSolutions, Inc. Research Report On November 7, 2013, Emergent BioSolutions Inc. (Emergent BioSolutions) reported its Q3 2013 financial results with total revenues of $89.1 million compared to $66.6 million in Q3 2012. Net income attributable to the Company totaled $13.5 million or $0.36 per diluted share compared to $6.6 million or $0.18 per diluted share in Q3 2012. Daniel J. Abdun-Nabi, President and CEO of Emergent BioSolutions commented, "We are very pleased with our financial results during the third quarter and first nine months of 2013." He concluded, "Finally, we continue to pursue acquisitions of additional products or companies that leverage our competencies and drive us toward achieving the goals identified in our growth plan." For full-year 2013 the Company anticipates total revenues to be in the range of $300 million to $310 million and net income to be between $25 million to $30 million. The Full Research Report on Emergent BioSolutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b2cc_EBS] -- ImmunoGen Inc. Research Report On November 5, 2013, ImmunoGen, Inc. (ImmunoGen) announced the initiation of clinical testing with its EGFR-targeting antibody-drug conjugate (ADC), IMGN289, which is designed to bind to and kill cancer cells that highly express EGFR, also known as HER1. Dr. Charles Morris, Executive Vice President and Chief Development Officer stated, "There is a lot of excitement around IMGN289. It is an antibody-drug conjugate, or ADC, to a well-known target, EGFR, and a potential new treatment for several types of cancers - including squamous cell lung and head and neck cancers - that have very limited treatment options today. We are delighted to now be gaining clinical experience with this promising new agent." The Full Research Report on ImmunoGen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/11c8_IMGN] -- Sequenom Inc. Research Report On November 7, 2013, Sequenom, Inc. (Sequenom) reported its Q3 2013 financial results. Total revenues for the quarter were of $44 million, representing a 92.3% YoY increase. Net loss totaled $28.1 million or $0.24 per diluted share in Q3 2013 compared to $30.2 million or $0.26 per share in Q3 2012. Commenting on the results, Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom stated, "We are proud to report record-breaking revenues for the third quarter, which primarily resulted from the continued adoption of the MaterniT21™ PLUS test. In October, we marked the second anniversary of the launch of Sequenom Laboratories industry-leading noninvasive prenatal test (NIPT) by announcing additional content for our MaterniT21 PLUS test. We began to report the presence of subchromosomal microdeletions and autosomal trisomies for chromosomes 16 and 22." The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d291_SQNM] -- Intrexon Corporation Research Report On November 7, 2013, Intrexon Corp. (Intrexon) reported its Q3 2013 financial results with revenues of $6.1 million compared to $2.9 million in Q3 2012. According to the Company, the increase in revenue resulted primarily from the recognition of deferred revenue for upfront payments received from five collaborations signed by Intrexon between October 1, 2012 and September 30, 2013, and one milestone payment received in October 2012. Net income attributable to common shareholders during the quarter was at $8.3 million or $0.15 per diluted share compared to a net loss attributable to common shareholders of $26 million or 4.66 per diluted share in Q3 2012. The Full Research Report on Intrexon Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cb5c_XON] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 1.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 2.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 3.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Public Offerings, Clinical Tests, and Financial Results- Research Report on InterMune, Emergent BioSolutions, ImmunoGen,
Press spacebar to pause and continue. Press esc to stop.